Dynavax Technologies | DVAX - Selling And Administration Expenses


Dynavax Technologies reported $40.09M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Adma Biologics USD 23.05M 320K Sep/2025
Amgen USD 1.7B 9M Sep/2025
AstraZeneca USD 148M 4.86B Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Dynavax Technologies USD 40.09M 1.45M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Merck USD 2.63B 0 Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025